Total Payments
$33,198
2021 Payments
$7,250
Companies
3
Transactions
40
Medicare Patients
581
Medicare Billing
$154,897
Payment Breakdown by Category
Other$29,936 (90.2%)
Consulting$1,396 (4.2%)
Travel$1,304 (3.9%)
Food & Beverage$561.27 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,936 | 17 | 90.2% |
| Consulting Fee | $1,396 | 2 | 4.2% |
| Travel and Lodging | $1,304 | 7 | 3.9% |
| Food and Beverage | $561.27 | 14 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $33,097 | 37 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $63.01 | 1 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $37.49 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $7,250 | 4 | Neurocrine Biosciences, Inc. ($7,250) |
| 2020 | $3,232 | 3 | Neurocrine Biosciences, Inc. ($3,232) |
| 2019 | $21,878 | 30 | Neurocrine Biosciences, Inc. ($21,815) |
| 2018 | $815.10 | 2 | Neurocrine Biosciences, Inc. ($800.00) |
| 2017 | $22.39 | 1 | Sunovion Pharmaceuticals Inc. ($22.39) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: NEUROLOGY | ||||||
| 09/21/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: NEUROLOGY | ||||||
| 09/15/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: NEUROLOGY | ||||||
| 07/29/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEUROLOGY | ||||||
| 10/28/2020 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $336.00 | General |
| Category: NEUROLOGY | ||||||
| 06/25/2020 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Consulting Fee | Cash or cash equivalent | $896.00 | General |
| Category: NEUROLOGY | ||||||
| 01/21/2020 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROLOGY | ||||||
| 10/29/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | Cash or cash equivalent | $117.16 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $57.42 | General |
| Category: NEUROLOGY | ||||||
| 10/16/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROLOGY | ||||||
| 08/22/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| Category: NEUROLOGY | ||||||
| 08/22/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Travel and Lodging | Cash or cash equivalent | $85.84 | General |
| Category: NEUROLOGY | ||||||
| 08/05/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $150.00 | General |
| Category: NEUROLOGY | ||||||
| 08/01/2019 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $63.01 | General |
| Category: Central Nervous System | ||||||
| 06/04/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROLOGY | ||||||
| 06/04/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $8.82 | General |
| Category: NEUROLOGY | ||||||
| 05/07/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROLOGY | ||||||
| 05/07/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $5.44 | General |
| Category: NEUROLOGY | ||||||
| 05/06/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $0.60 | General |
| Category: NEUROLOGY | ||||||
| 04/30/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROLOGY | ||||||
| 04/02/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROLOGY | ||||||
| 03/22/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $10.22 | General |
| Category: NEUROLOGY | ||||||
| 03/16/2019 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 93 | 431 | $56,778 | $24,885 |
| 2022 | 6 | 132 | 635 | $84,793 | $35,317 |
| 2021 | 7 | 176 | 626 | $90,076 | $41,974 |
| 2020 | 7 | 180 | 729 | $107,383 | $52,720 |
Total Patients
581
Total Services
2,421
Medicare Billing
$154,897
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 129 | $22,105 | $11,709 | 53.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 231 | $29,349 | $11,593 | 39.5% |
| Q3014 | Telehealth originating site facility fee | Office | 2023 | 14 | 59 | $3,776 | $1,167 | 30.9% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 12 | 12 | $1,548 | $415.44 | 26.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 215 | $36,550 | $16,878 | 46.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 51 | 231 | $29,256 | $11,338 | 38.8% |
| 99335 | Established patient custodial care facility, group care, or assisted living visit, typically 25 minutes | Office | 2022 | 11 | 56 | $5,112 | $3,206 | 62.7% |
| Q3014 | Telehealth originating site facility fee | Office | 2022 | 16 | 84 | $5,376 | $1,613 | 30.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 18 | 18 | $4,500 | $1,208 | 26.9% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 17 | 31 | $3,999 | $1,073 | 26.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 63 | 287 | $36,943 | $16,810 | 45.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 198 | $33,660 | $15,917 | 47.3% |
| 99335 | Established patient assisted living visit, typically 25 minutes | Office | 2021 | 16 | 55 | $5,977 | $3,807 | 63.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $3,240 | $1,869 | 57.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 22 | 22 | $5,500 | $1,738 | 31.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 20 | 21 | $2,772 | $1,185 | 42.7% |
| Q3014 | Telehealth originating site facility fee | Office | 2021 | 19 | 31 | $1,984 | $648.60 | 32.7% |
| G0408 | Follow-up inpatient consultation, complex, physicians typically spend 35 minutes communicating with the patient via telehealth | Office | 2020 | 39 | 365 | $54,750 | $29,970 | 54.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 57 | 207 | $26,183 | $10,138 | 38.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 44 | $7,480 | $3,523 | 47.1% |
| G0427 | Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth | Office | 2020 | 22 | 22 | $5,500 | $3,499 | 63.6% |
| 99335 | Established patient assisted living visit, typically 25 minutes | Office | 2020 | 14 | 31 | $4,320 | $2,074 | 48.0% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2020 | 14 | 39 | $3,900 | $1,820 | 46.7% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 21 | 21 | $5,250 | $1,697 | 32.3% |
About Dr. John Simon, M.D
Dr. John Simon, M.D is a Psychiatry healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255374609.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Simon, M.D has received a total of $33,198 in payments from pharmaceutical and medical device companies, with $7,250 received in 2021. These payments were reported across 40 transactions from 3 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($29,936).
As a Medicare-enrolled provider, Simon has provided services to 581 Medicare beneficiaries, totaling 2,421 services with total Medicare billing of $154,897. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Minneapolis, MN
- Active Since 06/14/2006
- Last Updated 10/19/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255374609
Products in Payments
- INGREZZA (Drug) $33,097
- AUSTEDO (Drug) $63.01
- LATUDA (Drug) $37.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Minneapolis
Dr. Sophia Vinogradov, Md, MD
Psychiatry — Payments: $33,782
Psychiatry $33,782
Ziad Nahas, Md, MD
Psychiatry — Payments: $21,831
Psychiatry $21,831
Dr. Alik Widge, M.d., Ph.d, M.D., PH.D
Psychiatry — Payments: $13,727
Psychiatry $13,727
Dr. Brian Johns, Md, Mfa, MD, MFA
Psychiatry — Payments: $6,599
Psychiatry $6,599
Dr. Gihyun Yoon, M.d, M.D
Psychiatry — Payments: $3,607
Psychiatry $3,607
Nisha Fernandes
Psychiatry — Payments: $2,051
Psychiatry $2,051